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What Happened to Research in Clinical Microbiology
in the United States?
Paul P. Bourbeau1* and Carey-Ann D. Burnham2
Geisinger Medical Center, Danville, Pennsylvania,1 and Departments of Pediatrics and Pathology & Immunology,
Washington University School of Medicine, St. Louis, Missouri2
The title of this article is loaded with negative innuendo—
the question is not “What is the state of research in clinical
microbiology in the United States” but, rather, “What has
happened to happened to research in clinical microbiology in
the United States.” We begin with the premise that there has
been a decline in the amount of clinical microbiology research
in the United States in recent years, present evidence support-
ing that premise, and offer some reasons why we believe that
this has occurred. In addition to this, we also suggest some
approaches that could be attempted to reverse this trend.
One metric that can be used to measure clinical microbiol-
ogy research in the United States is the number of manuscripts
published by authors employed by American institutions in the
Journal of Clinical Microbiology (JCM), which is arguably the
most prominent clinical microbiology journal in the United
States. Figure 1 summarizes the relative number of manu-
scripts submitted and published from 1975 to 2010 by Ameri-
can and non-American authors. Clearly, there was a significant
decline in the percentage of manuscripts submitted to and
manuscripts published by JCM by authors from the United
States from 1980 to 2005 compared with the number of man-
uscripts submitted to and manuscripts published by authors
from outside of the United States. As shown in Fig. 2, the
proportionate decline in manuscripts from American authors
cannot be explained by an increase in manuscripts from non-
American authors. Indeed, the number of manuscripts submit-
ted and published by American authors has declined steadily
over the past 30 years. When the number of manuscripts pub-
lished by American authors is divided into 3 groups—hospital/
university (H-U), government (national or state labs)/H-U col-
laboration, and industry/H-U collaboration—a decline is noted
in each group. It is noteworthy that publications arising from
collaborations with industry have become nearly nonexistent in
recent years.
One explanation for the decline in the number of manu-
scripts published by American authors in JCM could be that
authors are choosing to publish in journals that may be clini-
cally germane to the data being presented, such as pediatric,
infectious disease, or obstetric-gynecology journals. By pub-
lishing in these clinical journals, authors may believe that they
are better targeting end users of their research with informa-
tion that can help them make decisions in their clinical prac-
tice, as well as increasing the visibility of the profession of
clinical microbiology to clinicians. By publishing in the journal
for our own profession, i.e., microbiology, we are “preaching to
the choir,” with less opportunity to reach the end user and
influence clinical practice. However, our group concluded that
while some authors may be targeting these clinical discipline-
specific journals, this alone does not account for the drop in
publications by American authors in JCM.
It appears that the decline in American publications is not
unique to clinical microbiology; there was an overall decline in
U.S. representation in clinical research journals from 1977 to
1988, as reported by Stossel and Stossel (4). Specifically, this
study looked at the New England Journal of Medicine, the
Journal of Clinical Investigation, and the Lancet and in a spe-
cialty journal, Blood. During this period, the proportion of
papers from outside the United States increased between 2-
and 3-fold. Most non-U.S. research published originated in
Western Europe or Japan. This decline coincided with the
slowed growth of funding for clinical research from the NIH.
A specific example of the decline in the number of publica-
tions by clinical microbiologists was cited by Gary Doern at the
1998 General Meeting of the American Society for Microbiol-
ogy (ASM). He randomly identified 10 clinical microbiologists
from academic medical centers who presented lectures at the
1988 ASM meeting and compared their publication record for
the 5 years prior to that meeting with the publication record of
a similar group of 10 individuals from the 1998 meeting for the
5-year period prior to that meeting. In 1988, the 10 speakers
had published a mean of 6.2 articles per year in peer-reviewed
journals, while in 1998, the 10 speakers had published a mean
of 1.1 articles per year in peer-reviewed journals (1). Although
anecdotal, Doern’s data are consistent with the experience and
impressions of our group.
FACTORS CONTRIBUTING TO THE DECLINE IN
CLINICAL MICROBIOLOGY RESEARCH
What does account for the decline in clinical microbiology
research in the United States? There would seem to be several
not mutually exclusive explanations.
Government oversight/regulation. The regulatory environ-
ment for clinical laboratories and manufacturers of laboratory
devices and instruments has become increasingly complex and
cumbersome over the past 20 years or more. The cost for
manufacturers to complete Food and Drug Administration
(FDA) in vitro diagnostic product (IVD) submissions has in-
creased significantly, with a general perception that the FDA
has become much more restrictive. This environment has had
the effect of stifling IVD submissions and the concurring val-
idation studies. Conflict-of-interest policies, driven at least in
part by government oversight, have made collaborations with
* Corresponding author. Mailing address: Division of Laboratory
Medicine, Geisinger Medical Center, Danville, PA 17822-0131. Phone:
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industry increasingly burdensome. At one time, the presenta-
tion of the results of product validations at national meetings
was a commonplace occurrence. Today, industry has tight re-
strictions on when, how, and if this can occur because of con-
cerns related to illegal endorsements. It is our impression that
some manufacturers have shied away from providing research
support because of concerns that they may be perceived to be
supporting or condoning an illegal relationship with the labo-
ratory, even if that is not actually the case.
In many institutions, the institutional review board (IRB)
process is viewed as a significant impediment to performing
clinical research. It is our belief that the IRB process has
become progressively more complex, and it is viewed by many
laboratorians to be overly burdensome. Much attention has
been devoted to approaches and controversies regarding in-
formed consent and confidentiality when obtaining and using
human specimens in research protocols (2). This can be an
impediment to conducting research.
Some laboratory directors now find the IRB process at their
institutions to be so onerous that they have chosen to reduce or
eliminate research activities. Thus, some directors have found
the returns from these activities not to be worth the effort
expended and feel disincentivized to perform this work.
In addition, in some institutions, the actual members of the
IRB may have limited knowledge of the discipline of clinical
microbiology. An example of this is the failure of IRBs at some
of our institutions to recognize the difference between a mi-
crobial isolate and the specimen from which the isolate was
obtained when evaluating a research protocol. This has been
identified as an impediment to participating in scholarly activ-
ities; for example, some institutions are unable to submit clin-
ical isolates to national collaborative antimicrobial susceptibil-
ity studies, studies that provide information of much potential
benefit to the public health.
Changing mission of public health laboratories. There has
been a shift in the mission of the Centers for Disease Control
and Prevention (CDC) and the state public health labs over the
last number of years. While much clinical microbiology re-
search continues to be performed and published by microbiol-
ogists at the CDC, the mission of the CDC has changed, with
the result that the breadth of that research has narrowed.
Furthermore, many state public health laboratories have un-
dergone significant downsizing, often driven by fiscal con-
straints and fewer resources for pursuit of research activities.
The implications of this downsizing on the public health of the
United States unfortunately go far beyond a lack of support for
research activities.
Consolidation of manufacturers. The consolidation of man-
ufacturers, whether by merger/acquisitions or manufacturers
leaving the market, has also negatively impacted clinical mi-
crobiology research. This has occurred with medium manufac-
turers as well as with device and equipment manufacturers.
With fewer competitors in the market, there may be less in-
centive for industry to initiate studies to demonstrate the su-
perior performance of a company’s product versus a compet-
itor’s. Fewer new products are being developed and submitted
for IVD clearance, in part due to the regulatory atmosphere
that we have previously mentioned but also because there is
FIG. 1. Relative number of submissions to and publications in the Journal of Clinical Microbiology by American and non-American authors.
Values from 1985 to 2010 (courtesy of Charles Brown, ASM) were based on the total number of articles submitted or published for the entire year
in each of the 5-year intervals. Acceptance values for 1975 and 1980 were based on data tabulated from the January issue for each of those years.
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little impetus or incentive for companies to devote funds to
performing studies or promote products that are considered to
be already established and proven, especially if these are al-
ready commanding market share.
Changes in the pharmaceutical industry have also impacted
clinical microbiology research. There has been a decline in the
introduction of new antibiotics, a trend that likely will continue
in the near future, with almost no new antimicrobial agents in
the pipeline. A paucity of new antibiotics impacts FDA sub-
mission studies, marketing studies to test collections of isolates
to determine the efficacy of these agents against different mi-
crobes, and validation of antimicrobial testing methods and
devices. Another downstream effect of the introduction of
fewer new antibiotics is a decline in the number of studies
sponsored by pharmaceutical and device manufacturers to sup-
port CLSI guideline development for these new antibiotics.
Purchasing groups. In an effort to reduce reagent and
equipment costs, most laboratories belong to one or more
purchasing groups. Membership in these groups usually man-
dates purchase of specific laboratory diagnostic reagents and
equipment. In addition to potentially forcing a laboratory to
use a less optimal product for its specific needs, this has the
effect of limiting the opportunity for validation studies (and,
ultimately, publication) of alternate products that are not in-
cluded in the purchasing group contracts. Similar situations
exist with large reference laboratories, where use of noncon-
tract products may be precluded. The growth of the influence
of purchasing groups may also have had an unintended conse-
quence of making it more difficult for start-up companies to get
into the market, despite the potential innovativeness of their
products. The ultimate effect is to make it more costly and
time-consuming for new products to make it into the lab,
thereby limiting the opportunity for published validation stud-
ies that were much more common some years ago.
Industry collaborations. Historically, industry contributed a
certain number of publications, either independently or in col-
laboration with microbiologists in the field. More recently,
publications from industry have become nearly nonexistent in
JCM. The reticence of industry to participate in such activities
is at least in part due to conflict-of-interest constraints, a bar-
rier to these types of publications in recent times. It is apparent
to us that perceived or real conflicts of interest have negatively
impacted research support, particularly for things like travel
support for presentation of validation studies. Just like medical
directors, industry may feel disincentivized to initiate or par-
ticipate in studies.
Moreover, the contract negotiation process has become in-
creasingly more complex and time-consuming (due to both
industry and hospital/university constraints) for the principal
investigator (PI). The increasing outlay of time often yields
marginal benefits to the career of the PI. Furthermore, with
increasing overhead, IRB, and publication costs, it may be
impossible to get sufficient funds from such studies for them to
be considered to be of significant value.
Hospital laboratory constraints. Multiple constraints con-
tribute to reduced research being performed in hospital labo-
ratories. Hospital laboratories are increasingly focused almost
exclusively on patient testing, with less and less time and re-
sources available for research. Laboratories are usually looked
upon as revenue-generating centers by hospital administrators,
who often are struggling to keep their institutions fiscally sol-
vent. As noted by Sintchenko and Gilbert, laboratory medicine
FIG. 2. Number of publications by American authors in the Journal of Clinical Microbiology for January issues at 5-year intervals from January
1976 until January 2011. In addition to the total number of publications, separate numbers are provided for publications with authors from
hospitals or universities, national or state public health laboratories with collaboration from hospitals or universities, and industry with collabo-
ration from hospitals or universities.
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professionals have been increasingly burdened in recent years
by a somewhat relentless increase in requirements to improve
the efficiency and effectiveness of laboratory practice. Cost-
reduction strategies have had a negative impact on research
and development in clinical microbiology (3).
In the hospital environment, it is not always clear who
should pay for test development. New lab tests are typically
developed by or under the direction of the lab director, who
may or may not be an employee of the hospital. The lab
director may have to use his or her own resources/discretionary
funds to pay a technologist to develop such tests. However,
once the tests are introduced into clinical use, it is the hospital
that will benefit from this development, both with revenues and
with improved patient care. It is important for the laboratory
director to communicate these development activities back to
the hospital and the administration so that they understand the
impact of this work and are motivated to devote resources to
research activities with direct patient impact. However, with all
of the other demands now placed upon the director, develop-
ing this presence is time-consuming and can take time away
from other activities.
Space for performing studies has become a significant issue
in many laboratories. Even if monetary resources can be pro-
cured for equipment, there may physically be no space to do
this work in the laboratory. Laboratories compete with other
areas of the hospital for what is often diminishing capital pools.
Even though test menus and test volumes are growing, the
growth of space in many laboratories has not kept pace.
The individual(s) actually performing the research has also
become a significant issue. Previously, the “regular” med tech
in the laboratory would be able to work on studies following
completion of his or her daily clinical duties. However, with
staffing vacancies and increasing workloads, this has become
next to impossible for many laboratories. Being able to ade-
quately staff the lab for even essential clinical functions has
become an issue. Even if the monetary resources are available,
qualified individuals to perform the work may not exist. If the
lab is short staffed and folks are already working overtime, it is
very unlikely that these individuals will want to prolong their
working hours for research activities. Moreover, individuals in
the laboratory workforce are aging and arguably working
harder than they did earlier in their careers. These demands
result in reduced motivation for contributing to research pro-
jects and/or participating in continuing education activities.
Separate funds are now typically required to pay a person
dedicated to work on studies, if funds and space can even be
secured for such work.
Increasing demands placed upon microbiology laboratory
directors. In our opinion, one of the major hurdles to micro-
biology research is the increased demands that are placed on
the laboratory director on a daily basis and upon the clinical
laboratory in general. We note that, compared with their re-
sponsibilities 10 or 20 years ago, most microbiology lab direc-
tors are now responsible for a larger diversity of testing areas,
as well as more tests and more people. Indeed, many directors
are now responsible for testing of specimens from more than
one hospital, if not for the actual direction of more than one
hospital microbiology laboratory. The demands of keeping sci-
entifically up to date in all of the areas for which we are
responsible is extremely time-consuming. As an example, one
of us (P.P.B.) directs a lab that in 1993 performed about
100,000 total microbiology tests, including no molecular mi-
crobiology tests. This year, the same laboratory will perform
400,000-plus tests, including 100,000-plus molecular microbi-
ology tests for 19 analytes on 5 platforms. The current scientific
and administrative responsibilities placed upon directors often
leave little if any time for research.
As reported by Check, a number of prominent laboratory
directors reported increasing demands on their time and indi-
cated by consensus that the result is the creation of an envi-
ronment that is not conducive to clinical research and devel-
opment (1). One reason noted for this is that the lab director
has less time for research and test validation but has an in-
creasing burden of responsibility for financial management and
implementation of cost-containment strategies (1). That is, lab
directors are forced to spend more time on the business as-
pects of the laboratory, with less time for scientific endeavors
such as test development and/or basic research (1).
Reduced “value” placed on research by hospital/university
administration. At one time, the university-based clinical mi-
crobiologist was expected to perform research and publish in
order to obtain tenure and advance in rank. Today, many
universities have established “clinical tracks” which have the
effect of deemphasizing the importance of research. On a mon-
etary level, directors are often encouraged to devote most of
their time to clinical service. “Relative value units” of clinical
service may determine salary. Thus, what are the incentives to
do research? It may not enhance one’s salary or track for
promotion, dissuading many folks from devoting significant
time and energy to this.
SOLUTIONS
We can summarize the information that we have provided in
this article by simply stating that the current state of research
in clinical microbiology is in decline and threatened.
It is not clear to us that the decline in clinical microbiology
research can be reversed, but we offer the following sugges-
tions as possible solutions to at least some of the problems that
we have identified.
IRB involvement. We as microbiologists need to participate
on IRB committees to represent the needs of the laboratory in
research. We can educate our IRB colleagues to make reason-
able, informed decisions about approaches to regulations and
research protocols.
Collaboration with clinical colleagues. We need to collabo-
rate more than we have in the past with other clinical col-
leagues on studies. We need to ask them what studies or issues
they are interested in and provide microbiology expertise and
laboratory support to get these done. This approach helps the
field by bridging the collaborations and increasing the visibility
of the lab, helps give the collaborators information that they
may find helpful, and also spreads some of the burden caused
by IRBs, contracts, etc. This is particularly possible in the
medical school environment, where we can engage our trainees
(fellows, residents, and medical students) to participate. None-
theless, we recognize that overhead, as represented by indirect
costs, can be a major barrier to research in the medical school/
university setting. Many laboratorians have found that high
overhead charges have contributed to “pricing themselves out
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of the market.” This is a challenge in the academic environ-
ment.
Collaboration with other microbiologists. It was recognized
that microbiologists need to collaborate among themselves to
be more effective researchers. Collaborative efforts both re-
duce the individual effort required and add robustness to stud-
ies. Collaboration may make it possible to acquire more clin-
ical outcome data, as well as circumvent issues such as clonality
that may be encountered by performing a study in only a very
small patient population or subset of organisms. There are also
different skill sets, equipment, etc., in different centers, so this
approach can capitalize on the best of everyone’s assets.
Data mining. We should try to do studies with information
that we already have available to us, and this does not have to
cost a lot of money. We can do data mining from our labora-
tory information systems or electronic medical records, pro-
viding data to our health care administrators to help them
understand what we do and the impact that this can have on
patient care, etc. The lab director should be encouraged to
build a good relationship with the health care administration
team, take the data that he or she generates to the health care
administration team, and help to optimize practices and hos-
pital procedures. By highlighting these studies to the end users,
we can hope to enact change. We need to promote ourselves
and what we do. This gives us credibility not only within our
profession but also in the hospital setting with both adminis-
trative and clinical colleagues.
While the prevailing tone of this article is somewhat grim,
we urge and challenge our colleagues to continue to pursue
quality research in clinical microbiology. It is essential to the
advancement of our profession and for improved care for pa-
tients.
Session discussants: Kim Chapin, Stacey Klutts, Nathan Ledeboer,
Mike Saubolle, Gongyi Shi, Michael Towns, and Ben Turng.
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